Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

42.00 +0.92 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Earnings Preview: Mirum Pharmaceuticals
Via Benzinga
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in... 
Via Benzinga
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease
Via Benzinga
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.